173 related articles for article (PubMed ID: 37758594)
1. Cost-effectiveness of nirsevimab and palivizumab for respiratory syncytial virus prophylaxis in preterm infants 29-34 6/7 weeks' gestation in the United States.
Yu T; Padula WV; Yieh L; Gong CL
Pediatr Neonatol; 2024 Mar; 65(2):152-158. PubMed ID: 37758594
[TBL] [Abstract][Full Text] [Related]
2. The cost-effectiveness of palivizumab for respiratory syncytial virus prophylaxis in premature infants with a gestational age of 32-35 weeks: a Canadian-based analysis .
Lanctôt KL; Masoud ST; Paes BA; Tarride JE; Chiu A; Hui C; Francis PL; Oh PI
Curr Med Res Opin; 2008 Nov; 24(11):3223-37. PubMed ID: 18928643
[TBL] [Abstract][Full Text] [Related]
3. Cost-utility analysis of Palivizumab for Respiratory Syncytial Virus infection prophylaxis in preterm infants: update based on the clinical evidence in Spain.
Sanchez-Luna M; Burgos-Pol R; Oyagüez I; Figueras-Aloy J; Sánchez-Solís M; Martinón-Torres F; Carbonell-Estrany X
BMC Infect Dis; 2017 Oct; 17(1):687. PubMed ID: 29041909
[TBL] [Abstract][Full Text] [Related]
4. Immunoprophylaxis against respiratory syncytial virus (RSV) with palivizumab in children: a systematic review and economic evaluation.
Wang D; Cummins C; Bayliss S; Sandercock J; Burls A
Health Technol Assess; 2008 Dec; 12(36):iii, ix-x, 1-86. PubMed ID: 19049692
[TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness analysis of palivizumab as respiratory syncytial virus prophylaxis in preterm infants in Sweden.
Neovius K; Buesch K; Sandström K; Neovius M
Acta Paediatr; 2011 Oct; 100(10):1306-14. PubMed ID: 21477089
[TBL] [Abstract][Full Text] [Related]
6. [The efficiency (cost-effectiveness) of palivizumab as prophylaxis against respiratory syncytial virus infection in premature infants with a gestational age of 32-35 weeks in Spain].
Lázaro y de Mercado P; Figueras Aloy J; Doménech Martínez E; Echániz Urcelay I; Closa Monasterolo R; Wood Wood MA; Fitch Warner K
An Pediatr (Barc); 2006 Oct; 65(4):316-24. PubMed ID: 17020726
[TBL] [Abstract][Full Text] [Related]
7. Updated cost-effectiveness analysis of palivizumab (Synagis) for the prophylaxis of respiratory syncytial virus in infant populations in the UK.
Narayan O; Bentley A; Mowbray K; Hermansson M; Pivonka D; Kemadjou EN; Belsey J
J Med Econ; 2020 Dec; 23(12):1640-1652. PubMed ID: 33107769
[TBL] [Abstract][Full Text] [Related]
8. Palivizumab for immunoprophylaxis of respiratory syncytial virus (RSV) bronchiolitis in high-risk infants and young children: a systematic review and additional economic modelling of subgroup analyses.
Wang D; Bayliss S; Meads C
Health Technol Assess; 2011 Jan; 15(5):iii-iv, 1-124. PubMed ID: 21281564
[TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness of rule-based immunoprophylaxis against respiratory syncytial virus infections in preterm infants.
Blanken MO; Frederix GW; Nibbelke EE; Koffijberg H; Sanders EAM; Rovers MM; Bont L;
Eur J Pediatr; 2018 Jan; 177(1):133-144. PubMed ID: 29168012
[TBL] [Abstract][Full Text] [Related]
10. Cost-effectiveness of respiratory syncytial virus prophylaxis among preterm infants.
Joffe S; Ray GT; Escobar GJ; Black SB; Lieu TA
Pediatrics; 1999 Sep; 104(3 Pt 1):419-27. PubMed ID: 10469764
[TBL] [Abstract][Full Text] [Related]
11. Cost effectiveness of palivizumab for respiratory syncytial virus prophylaxis in high-risk children: a UK analysis.
Nuijten MJ; Wittenberg W; Lebmeier M
Pharmacoeconomics; 2007; 25(1):55-71. PubMed ID: 17192118
[TBL] [Abstract][Full Text] [Related]
12. Cost-effectiveness analysis of palivizumab among pre-term infant populations covered by Medicaid in the United States.
Weiner LB; Masaquel AS; Polak MJ; Mahadevia PJ
J Med Econ; 2012; 15(5):997-1018. PubMed ID: 22435648
[TBL] [Abstract][Full Text] [Related]
13. Palivizumab for respiratory syncytial virus prophylaxis in high-risk infants: a cost-effectiveness analysis.
Lofland JH; O'Connor JP; Chatterton ML; Moxey ED; Paddock LE; Nash DB; Desai SA
Clin Ther; 2000 Nov; 22(11):1357-69. PubMed ID: 11117660
[TBL] [Abstract][Full Text] [Related]
14. Cost utility of palivizumab prophylaxis among pre-term infants in the United States: a national policy perspective.
Mahadevia PJ; Masaquel AS; Polak MJ; Weiner LB
J Med Econ; 2012; 15(5):987-96. PubMed ID: 22574798
[TBL] [Abstract][Full Text] [Related]
15. Respiratory syncytial virus and premature infants born at 32 weeks' gestation or earlier: hospitalization and economic implications of prophylaxis.
Stevens TP; Sinkin RA; Hall CB; Maniscalco WM; McConnochie KM
Arch Pediatr Adolesc Med; 2000 Jan; 154(1):55-61. PubMed ID: 10632251
[TBL] [Abstract][Full Text] [Related]
16. Respiratory syncytial virus prophylaxis in preterm infants: a cost-effectiveness study from Turkey.
Oncel MY; Mutlu B; Kavurt S; Baş AY; Demirel N; Akyol M; Erdeve O; Dilmen U
Turk J Pediatr; 2012; 54(4):344-51. PubMed ID: 23692714
[TBL] [Abstract][Full Text] [Related]
17. Monoclonal antibody for reducing the risk of respiratory syncytial virus infection in children.
Andabaka T; Nickerson JW; Rojas-Reyes MX; Rueda JD; Bacic Vrca V; Barsic B
Cochrane Database Syst Rev; 2013 Apr; (4):CD006602. PubMed ID: 23633336
[TBL] [Abstract][Full Text] [Related]
18. Cost-effectiveness of palivizumab for respiratory syncytial virus infection in high-risk children, based on long-term epidemiologic data from Austria.
Resch B; Sommer C; Nuijten MJ; Seidinger S; Walter E; Schoellbauer V; Mueller WD
Pediatr Infect Dis J; 2012 Jan; 31(1):e1-8. PubMed ID: 21960187
[TBL] [Abstract][Full Text] [Related]
19. Palivizumab for Infants < 29 Weeks in Hong Kong without a Clear-Cut Season for Respiratory Syncytial Virus Infection-A Cost-Effectiveness Analysis.
Lee SR; Kwok KL; Ng DKK; Hon KL
J Trop Pediatr; 2018 Oct; 64(5):418-425. PubMed ID: 29106671
[TBL] [Abstract][Full Text] [Related]
20. Economic evaluation of possible prevention of RSV-related hospitalizations in premature infants in Germany.
Roeckl-Wiedmann I; Liese JG; Grill E; Fischer B; Carr D; Belohradsky BH
Eur J Pediatr; 2003 Apr; 162(4):237-44. PubMed ID: 12647196
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
